AI Image
Former Madrigal Pharma executive alleges coverup of drug safety issues
STAT • • business
Key Points:
- Michael Charlton, former senior vice president and head of clinical development at Madrigal Pharmaceuticals, has filed a federal lawsuit claiming he was forced to resign after raising safety concerns about the company’s liver disease medication for MASH patients.
- Charlton’s lawsuit, filed in the Northern District of Illinois, accuses Madrigal of retaliation under federal whistleblower-protection laws and seeks either reinstatement or monetary damages.
- The suit alleges that Charlton was tasked with ensuring the safety and scientific integrity of clinical trials for Madrigal’s flagship drug and was punished by the company for fulfilling that responsibility.
